Rasoul Shavaleh

Rasoul Shavaleh


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
KRKazem Rahmani
Kazem Rahmani
RSRasoul Shavaleh
Rasoul Shavaleh
MFMahtab Forouhi
Mahtab Forouhi
HDHamideh Feiz Disfani
Hamideh Feiz Disfani
MKMostafa Kamandi
Mostafa Kamandi
Mostafa DianatinasabMostafa Dianatinasab
Mostafa Dianatinasab
Background: Vaccination, one of the most important and effective ways of preventing infectious diseases, has recently been used to control the COVID-19 pandemic. The present meta-analysis study aimed to evaluate the effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19.Methods: A systematic search was performed independently in Scopus, PubMed via Medline, ProQuest, and Google Scholar electronic databases as well as preprint servers using the keywords under study. We used random-effect models and the heterogeneity of the studies was assessed using I2 and χ2 statistics. In addition, the Pooled Vaccine Effectiveness (PVE) obtained from the studies was calculated by converting based on the type of outcome.Results: A total of 54 studies were included in this meta-analysis. The PVE against SARS-COV 2 infection were 71% [odds ratio (OR) = 0.29, 95% confidence intervals (CI): 0.23–0.36] in the first dose and 87% (OR = 0.13, 95% CI: 0.08–0.21) in the second dose. The PVE for preventing hospitalization due to COVID-19 infection was 73% (OR = 0.27, 95% CI: 0.18–0.41) in the first dose and 89% (OR = 0.11, 95% CI: 0.07–0.17) in the second dose. With regard to the type of vaccine, mRNA-1273 and combined studies in the first dose and ChAdOx1 and mRNA-1273 in the second dose had the highest effectiveness in preventing infection. Regarding the COVID-19-related mortality, PVE was 68% (HR = 0.32, 95% CI: 0.23–0.45) in the first dose and 92% (HR = 0.08, 95% CI: 0.02–0.29) in the second dose.Conclusion: The results of this meta-analysis indicated that vaccination against COVID-19 with BNT162b2 mRNA, mRNA-1273, and ChAdOx1, and also their combination, was associated with a favorable effectiveness against SARS-CoV2 incidence rate, hospitalization, and mortality rate in the first and second doses in different populations. We suggest that to prevent the severe form of the disease in the future, and, in particular, in the coming epidemic picks, vaccination could be the best strategy to prevent the severe form of the disease.Systematic review registration: PROSPERO International Prospective Register of Systematic Reviews: http://www.crd.york.ac.uk/PROSPERO/, identifier [CRD42021289937].

3 November 2021 in medRxiv
Verified
Preprint
Open access
PDF file
KRKazem Rahmani
Kazem Rahmani
RSRasoul Shavaleh
Rasoul Shavaleh
MFMahtab Forouhi
Mahtab Forouhi
HDHamideh Feiz Disfani
Hamideh Feiz Disfani
MKMostafa Kamandi
Mostafa Kamandi
MSMoslem Soltani
Moslem Soltani
Introduction & Objective: Vaccination is one of the most important and effective ways of preventing infectious diseases, and has recently been used in the COVID-19 epidemic and pandemic. The present meta-analysis study aimed to evaluate the effectiveness of COVID-19 vaccines in reducing the incidence of infection, hospitalization, and mortality in observational studies. Materials and Methods: A systematic search was performed independently in Scopus, PubMed, ProQuest, and Google Scholar electronic databases as well as Preprint servers using the keywords under study. The heterogeneity of the studies was assessed using I 2 and χ 2 statistics, according to which the I 2 of > 50% and P -value <0.1 was reported as heterogeneity of the studies. In addition, the Pooled Vaccine Effectiveness (PVE) obtained from the studies was calculated by converting (1-Pooled estimate × 100%) based on the type of outcome. Results: A total of 54 records were included in this meta-analysis. The rate of PVE against SARS-COV 2 infection was about 71% (OR = 0.29, 95% CI: 0.23-0.36) in the first dose and 87% (OR = 0.13, 95% CI: 0.08-0.21) in the second, and the highest effectiveness in the first and second doses was that of BNT162b2 mRNA and combined studies. The PVE versus COVID-19-associated hospitalization was 73% (OR = 0.27, 95% CI: 0.18-0.41) in the first dose and 89% (OR = 0.11, 95% CI: 0.07-0.17) in the second. mRNA-1273 and combined studies in the first dose and ChAdOx1 and mRNA-1273 in the second dose had the highest effectiveness. Regarding the COVID-19-related mortality, PVE was about 28% (HR = 0.39, 95% CI: 0.23-0.45) in the first dose and 89% (HR = 0.11, 95% CI: 0.03-0.43) in the second. Conclusion: The evidence obtained from this study showed that the effectiveness of BNT162b2 mRNA, mRNA-1273, and ChAdOx1 in the first and second doses, and even combined studies were associated with increased effectiveness against SARS-COV2 infection, hospitalization, and death from COVID-19. In addition, considering that the second dose was significantly more efficient than the first one, a booster dose injection could be effective in high-risk individuals. On the other hand, it was important to observe other prevention considerations in the first days after taking the first dose.

29 November 2025 in Cancer Reports
Verified
Journal Article
Open access
HDHamideh Feiz Disfani
Hamideh Feiz Disfani
MRMahsan Ramezani
Mahsan Ramezani
MMMilad Moradi
Milad Moradi
MKMostafa Kamandi
Mostafa Kamandi
MFMolood Foogerdi
Molood Foogerdi
KRKazem Rahmani
Kazem Rahmani
Background: Evidence indicates that beta‐2 microglobulin (β2M) plays a prognostic role in patients with diffuse large B‐cell lymphoma (DLBCL). Aim: However, due to controversies among previous studies, this meta‐analysis was conducted to evaluate the prognostic role of β2M in DLBCL patients. Methods and Results: Relevant studies were identified through a systematic search using specific keywords in PubMed/Medline, Scopus, and Web of Science databases. Studies that provided complete information on the hazard ratio with a 95% confidence interval for β2M with respect to overall survival (OS) and progression‐free survival (PFS) in multivariate models were included in the meta‐analysis. A total of 30 studies, encompassing 25 128 patients, were included in this meta‐analysis. The pooled analysis demonstrated a significant association between elevated β2M levels and poor OS in DLBCL patients (HR Pooled : 1.65, 95% CI: 1.45–1.88, p ‐value < 0.01). Similarly, increased β2M levels were significantly associated with lower PFS in DLBCL patients (HR Pooled : 1.54, 95% CI: 1.39–1.70, p ‐value < 0.01). Conclusion: The available evidence suggests that β2M serves as an independent prognostic marker with significant effects on OS and PFS in DLBCL patients. Elevated serum β2M levels are associated with poor prognosis and worse OS and PFS outcomes in DLBCL patients.